Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
UnitedHealth Group
UNHHealthcareGenerated Jul 5, 2026, 08:13 PM UTC
UNH (UnitedHealth Group) analytical snapshot. Revenue grew +14.6% YoY to $371.62B. 5-year revenue CAGR +8.9%; 10y CAGR +12.3%. Net margin at 6.02% (expanding ▲). Market cap $386.29B at $425.36 per share. Trailing P/E 17.83, P/S 1.04, P/B 11.70. EV/Operating income ≈ 13.28 (EV $429.73B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score 6 (data confidence 83%). Descriptive analytics from public filings — not investment advice.
Market cap
$386.29B
908.14M shares
Price
$425.36
NYQ
P/E (ttm)
17.83
Revenue (FY)
$371.62B
YoY +14.6%
Net margin
6.02%
▲ 0.03pp
Free cash flow
$25.68B
6.91% margin
Risk level
Elevated
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score -15Stable
80% conf
Revenue grew +14.6% YoY to $371.62B. 5-year revenue CAGR +8.9%; 10y CAGR +12.3%. Net margin at 6.02% (expanding ▲).
- Revenue grew +14.6% YoY to $371.62B.
- 5-year revenue CAGR +8.9%; 10y CAGR +12.3%.
- Net margin at 6.02% (expanding ▲).
- Gross margin 0.00%, operating margin 8.71%.
- Free cash flow margin 6.91% ($25.68B).
- Net income up ▲ +11.2% YoY.
- Debt/equity 2.16, current ratio 0.80, net debt $43.44B.
- Asset turnover 1.19 — capital efficiency.
Revenue (FY)
$371.62B
YoY +14.6%
Net margin
6.02%
▲ 0.03pp
ROE
—
ROA 8.18%
ROIC
44.72%
EPS (diluted)
$23.86
FY2025
Free cash flow
$25.68B
6.91% margin
Debt / equity
2.16
Cash $28.00B
Current ratio
0.80
Equity $33.02B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | $130.47B | — | 0.00 | 7.87 | 4.31 | $6.53B | — |
| 2017 | $157.11B | +20.4% | 0.00 | 7.01 | 3.70 | $8.18B | — |
| 2018 | $184.84B | +17.7% | 0.00 | 7.00 | 3.80 | $8.09B | — |
| 2019 | $201.16B | +8.8% | 0.00 | 7.56 | 5.25 | $11.57B | — |
| 2020 | $226.25B | +12.5% | 0.00 | 7.67 | 5.30 | $13.65B | — |
| 2021 | $242.16B | +7.0% | 0.00 | 8.13 | 5.71 | $16.39B | — |
| 2022 | $257.14B | +6.2% | 0.00 | 8.71 | 5.99 | $20.12B | — |
| 2023 | $287.60B | +11.8% | 0.00 | 8.33 | 6.01 | $19.89B | — |
| 2024 | $324.16B | +12.7% | 0.00 | 8.77 | 6.21 | $23.40B | — |
| 2025 | $371.62B | +14.6% | 0.00 | 8.71 | 6.02 | $25.68B | — |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 31, 2025 | $109.58B | +9.8% | — | 5.74% |
| Jun 30, 2025 | $221.19B | +11.3% | +101.9% | 4.38% |
| Jun 30, 2025 | $111.62B | -43.8% | -49.5% | 8.69% |
| Sep 30, 2025 | $334.35B | +11.6% | +199.6% | 3.60% |
| Sep 30, 2025 | $113.16B | -62.2% | -66.2% | 10.65% |
| Mar 31, 2026 | $111.72B | +2.0% | -1.3% | 5.62% |
Revenue (annual, SEC 10-K)
2016: 130,474
2017: 157,107
2018: 184,840
2019: 201,159
2020: 226,247
2021: 242,155
2022: 257,141
2023: 287,597
2024: 324,162
2025: 371,622
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2016: 6,526
2017: 8,184
2018: 8,090
2019: 11,573
2020: 13,650
2021: 16,392
2022: 20,123
2023: 19,889
2024: 23,404
2025: 25,682
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 30Improving
80% conf
Latest annual report (10-K) filed Mar 2, 2026. Latest quarterly report (10-Q) filed May 5, 2026. 12 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Mar 2, 2026.
- Latest quarterly report (10-Q) filed May 5, 2026.
- 12 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference UnitedHealth Group; broad institutional reporting.
- Recent filers include Capital Wealth Planning, LLC, Capital Wealth Planning, LLC, Capital Wealth Planning, LLC.
- 4 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 16 recent 13G passive institutional ownership notices.
Latest 10-K
Mar 2, 2026
Annual report
Latest 10-Q
May 5, 2026
8-K (recent)
12
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
4
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| Capital Wealth Planning, LLC | 13F-HR | Feb 13, 2019 |
| Capital Wealth Planning, LLC | 13F-HR | Aug 13, 2018 |
| Capital Wealth Planning, LLC | 13F-HR | Nov 13, 2018 |
| Allen Investment Management LLC | 13F-HR | Nov 9, 2006 |
| VitalStone Financial, LLC | 13F-HR | Jan 30, 2023 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| Jun 5, 2026 | 8-K | 8-K |
| May 11, 2026 | 8-K | 8-K |
| Apr 21, 2026 | 8-K | 8-K |
| Mar 9, 2026 | 8-K | 8-K |
| Mar 2, 2026 | 8-K | 8-K |
| Feb 25, 2026 | 8-K | 8-K |
| Jan 27, 2026 | 8-K | 8-K |
| Jan 12, 2026 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -51Deteriorating
68% conf
3 risk signal(s), 1 positive signal(s), 4 watch item(s) detected from XBRL filing diff analysis. 3 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- Inventory buildup exceeds sales growth: Inventory grew +35.7% vs revenue +14.6%. Excess inventory may signal weakening demand, potential write-downs, or supply chain overcommitment. Watch gross margin for discounting impact.
- Material weakness in internal controls: The term "material weakness" appears in 23 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 9 filing(s).
- Operating cash flow exceeds net income: OCF is 1.30x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Goodwill is 35% of total assets: Goodwill of $110.51B represents a large share of the balance sheet. If acquired businesses underperform, a non-cash impairment charge could materially impact earnings. Monitor segment performance and acquisition integration metrics.
- NEW: Impairment charge: Impairment charge appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: 3 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 4 new risk-language term(s) detected in filing text: Restatement of financial statements, Impairment charge, Restructuring, Off-balance sheet arrangements.
- Ongoing high-severity risk language: Material weakness in internal controls.
Revenue
$371.62B
+14.6% YoY
Operating income
$32.36B
+13.8% YoY
Net income
$22.38B
+11.2% YoY
Operating cash flow
$29.07B
+10.9% YoY
Capex
$3.39B
+20.8% YoY
Total assets
$273.72B
+11.4% YoY
Total liabilities
$195.69B
+11.9% YoY
Long-term debt
$72.36B
+24.2% YoY
Filing quality score
65/100
stable
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $324.16B | $371.62B | $47.46B | +14.6% |
| Operating income | $28.43B | $32.36B | $3.92B | +13.8% |
| Net income | $20.12B | $22.38B | $2.26B | +11.2% |
| Operating cash flow | $26.21B | $29.07B | $2.86B | +10.9% |
| Capex | $2.80B | $3.39B | $584.0M | +20.8% |
| Total assets | $245.71B | $273.72B | $28.02B | +11.4% |
| Total liabilities | $174.80B | $195.69B | $20.89B | +11.9% |
| Long-term debt | $58.26B | $72.36B | $14.10B | +24.2% |
| Cash & equivalents | $25.43B | $25.31B | $-115.0M | -0.5% |
| Stockholders equity | $28.29B | $31.18B | $2.89B | +10.2% |
| Inventory | $2.80B | $3.80B | $1.00B | +35.7% |
| Accounts receivable | $21.28B | $22.36B | $1.09B | +5.1% |
| SG&A expense | $47.78B | $54.63B | $6.85B | +14.3% |
| Interest expense | $2.09B | $3.25B | $1.15B | +55.2% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Removed | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment, AllocatedShareBasedCompensationExpenseNetOfTax, AllowanceForDoubtfulAccountsReceivableCurrent, AllowanceForDoubtfulOtherReceivablesCurrent, AmortizationOfIntangibleAssets, BuildingsAndImprovementsGross, BusinessCombinationConsiderationTransferred1, BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets, BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents, BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Material weakness in internal controls | high | 23 | 2 | Ongoing |
| Restatement of financial statements | high | 9 | 0 | NEW |
| Impairment charge | medium | 17 | 0 | NEW |
| Restructuring | medium | 8 | 0 | NEW |
| Off-balance sheet arrangements | medium | 37 | 0 | NEW |
| Related party transactions | low | 1 | 1 | Ongoing |
Filing signal breakdown
Red flags: 3
Positive: 1
Watch: 4
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $386.29B at $425.36 per share.
- ProPrice & TechnicalsPrice $425.36 — uptrend (above 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Elevated.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite 6
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. UnitedHealth Group is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewMarket cap $386.29B at $425.36 per share..
Risk
Elevated
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow UNH stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH● you | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Zoetis Inc. ZTS | 3 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Gilead Sciences GILD | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Moderna Inc. MRNA | -4 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| DexCom Inc. DXCM | -7 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Vertex Pharmaceuticals VRTX | -8 | Neutral |
| Kimberly-Clark Corp. KMB | -10 | Neutral |
| Sysco Corp. SYY | -10 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Biogen Inc. BIIB | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Thermo Fisher Scientific TMO | -18 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |